Production (Stage)
Jasper Therapeutics, Inc.
JSPR
$6.05
$0.040.67%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -23.23% | -10.55% | -3.98% | -12.67% | -28.54% |
| Total Depreciation and Amortization | 21.57% | 23.92% | 28.51% | 5.14% | 8.62% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 64.04% | 14.77% | -2.75% | -1.89% | 18.73% |
| Change in Net Operating Assets | -119.10% | -96.22% | -138.49% | -96.11% | -78.75% |
| Cash from Operations | -21.30% | -20.23% | -20.14% | -21.74% | -36.89% |
| Capital Expenditure | -98.12% | -106.74% | -476.47% | -20.82% | 53.58% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -89.10% | -99.25% | -476.47% | -20.82% | 53.58% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -98.88% | -53.02% | -53.33% | -53.29% | -52.96% |
| Repurchase of Common Stock | -- | -- | 54.77% | 54.77% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -98.86% | -52.58% | -53.32% | -53.28% | -53.91% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -537.77% | -131.35% | -121.48% | -116.35% | -118.52% |